WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Companies > Hetero Drugs Ltd
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Business Insights
Atomwise | August 22, 2022
Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, announced that it has established a strategic and exclusive research collaboration with Sanofi that will leverage its AtomNet® platform for computational discovery and research of up to five drug targets. The Atomwise approach shifts the mode of drug discovery away from serendipitous discovery and toward search based on structure, making the drug discovery process more rational, effecti...
Pharmafile: Home | March 04, 2020
The decision was based on Phase 3 comparing Alunbrig to crizotinib in the same indication. The findings for Alunbrig showed a 69% reduction in risk of intracranial disease progression or death in patients with brain metastases according to a blinded independent review committee, and a 76% reduction according to investigators. The drug also demonstrated a median progression-free survival of 24 months, more than double the 11 months presented by crizotinib. Because of the complex nature of ALK+ NS...
IceCure Medical Ltd | August 30, 2022
IceCure Medical Ltd. developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing as an alternative to surgical tumor removal, announced it has submitted a regulatory filing with the Department of Medical Equipment and Construction of Vietnam's Ministry of Health for the ProSense System and accessories. The application covers indications including benign and malignant breast tumors, benign and malignant lung tumors, benign ...
Research
Newswire | July 05, 2023
Cipher Pharmaceuticals Inc. ("Cipher" or "the Company") today announced that the Company's partner, Moberg Pharma AB, ("Moberg Pharma") has obtained European Union approval for MOB-015 (nail fungus treatment) as a result of demonstrating superior levels of mycological cure (76% vs. 42% for comparators) and a significantly better complete cure rate. MOB-015 has been recommended for national approval in 13 European countries, which will be commerc...
Pharma Tech
Video
Pharmacy Market
Whitepaper
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE